Next 10 |
home / stock / flhlf / flhlf news
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , May 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage na...
2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...
FILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET Canada NewsWire VANCOUVER, BC , April 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or ...
FILAMENT HEALTH REPORTS Q4 AND YEAR END 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , April 2, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natur...
FILAMENT HEALTH ANNOUNCES APPOINTMENT OF MICHAEL MESSINGER TO ITS BOARD OF DIRECTORS Canada NewsWire VANCOUVER, BC , March 28, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage na...
FILAMENT HEALTH ANNOUNCES SHIPMENTS OF BOTANICAL PSILOCYBIN TO FOUR COUNTRIES FOR CLINICAL INVESTIGATION Canada NewsWire Research institutions in the United States , Canada , Israel , and Belgium , including Johns Hopkins University , will study PEX010, Fil...
--News Direct-- Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the groundbreaking news that the U.S. Food and Drug Administration (FDA) has given its approval for the Investigational New Drug application for PEX010, Filament Health's botanical psilocybin dr...
FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO ISRAEL Canada NewsWire Hadassah University Hospital will study PEX010, Filament's botanical psilocybin drug candidate, for the treatment of post-traumatic stress disorder and obsessive-compulsive disorder ...
FILAMENT HEALTH ANNOUNCES FDA OPENING OF INVESTIGATIONAL NEW DRUG APPLICATION FOR SUBSTANCE USE DISORDERS Canada NewsWire The active IND allows initiation of US research with Filament's botanical psilocybin drug candidate for the potential treatment of substance use disorders ...
FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO AUSTRALIA Canada NewsWire Reset Mind Sciences Ltd. has received a shipment of PEX010, Filament's botanical psilocybin drug candidate VANCOUVER, BC , Jan. 17, 2024 /CNW/ - Filament Healt...
News, Short Squeeze, Breakout and More Instantly...
Filament Health Company Name:
FLHLF Stock Symbol:
OTCMKTS Market:
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , May 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage na...
2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...
FILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET Canada NewsWire VANCOUVER, BC , April 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or ...